Navigation Links
Kaiser Permanente study: Change in PSA levels over time can help predict aggressive prostate cancer
Date:1/15/2013

PASADENA, Calif., January 15, 2013 Measurements taken over time of prostate specific antigen, the most commonly used screening test for prostate cancer in men, improve the accuracy of aggressive prostate cancer detection when compared to a single measurement of PSA, according to a Kaiser Permanente study published today in the British Journal of Urology International.

The retrospective study examined the electronic health records of nearly 220,000 men ages 45 and older over a 10-year period who had at least one PSA measurement and no previous diagnosis of prostate cancer. The study found that annual percent changes in PSA more accurately predicted the presence of aggressive prostate cancer when compared to single measurements of PSA alone, but only marginally improved the prediction of prostate cancer overall.

"The use of a single, elevated PSA level to screen for prostate cancer is considered controversial given the questionable benefits of PSA screening on prostate cancer mortality. The screening may also result in unnecessary prostate biopsies and subsequent treatments for localized prostate cancer, as it does not distinguish well between slow-growing and aggressive disease," said Lauren P. Wallner, PhD, MPH, study lead author and post-doctoral research fellow at Kaiser Permanente Southern California's Department of Research & Evaluation. "Our study demonstrates that repeated measurements of PSA over time could provide a more accurate and much needed detection strategy for aggressive forms of prostate cancer."

Men in the study were also found to experience a 2.9 percent change in PSA levels per year on average and that the rate of change in PSA increased modestly with age.

"The results of this study could provide clinicians with a better prostate cancer preventive strategy that could help differentiate between men with an aggressive form of the disease and those who have slow-growing, indolent cancer that may not
'/>"/>

Contact: Jacqueline Brown
jacqueline.brown@golinharris.com
415-318-4361
Kaiser Permanente
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. Study: Women not getting enough exercise; at risk of developing metabolic syndrome
2. Study: Insomnia takes toll on tinnitus patients
3. Study: No link between depression, nasal obstruction
4. Study: More Pre-Teens Get Vaccines When Middle Schools Require Them
5. Study: Kids Who Sleep in Parents Bed Less Likely to Be Overweight
6. OHSU study: Misdiagnosis of MS is costing health system millions per year
7. UW study: Sleep apnea associated with higher mortality from cancer
8. Study: Heart damage after chemo linked to stress in cardiac cells
9. STeleR study: Telerehab improves functioning after stroke
10. Study: Willingness to be screened for dementia varies by age but not by sex, race or income
11. Study: 21 percent of newly admitted nursing home residents sustain a fall during their stay
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2013)... 2013 Minor fender benders and serious ... require parties to the accident to respond appropriately to ... and Prevention (CDC) data from 2010, accidents, including car ... In fact, in 2005, automobile accident-related deaths ... more than 2.3 million drivers and passengers receive treatment ...
(Date:5/19/2013)... Columbus, OH (PRWEB) May 19, 2013 ... LLC continue to follow developments in the nation’s first ... The case, underway in Washington State Superior Court, was ... several years after he suffered complications in a robot-assisted ... The Da Vinci robotic surgery lawsuit ...
(Date:5/18/2013)... COOLA, British Columbia (PRWEB) May 19, 2013 ... to Cooking” (published by iUniverse) , author Janet Hall Svisdahl’s ... delectable world recipes sure to make even the pickiest ... living peacefully, pleasurably and prayerfully,” she explains. , Found ... Spirit” are a wide range of delicious recipes, from fast ...
(Date:5/18/2013)... 19, 2013 The American Society for Gastrointestinal Endoscopy ... endoscopy during the ninth annual ASGE Crystal Awards on ... ASGE Foundation, this year,s event will begin at ... Fla. , Held in conjunction with Digestive Disease ... in leadership, research and scientific pursuit. The event will ...
(Date:5/18/2013)... Bethesda, MD (May 19, 2013) The American ... announce its 2013 research scholars. This year,s honorees ... in gastroenterology, hepatology or related areas, and with ... , "These young researchers are the future ... young scholars who are paving the way for ...
Breaking Medicine News(10 mins):Health News:Auto Accident Infographic Issued by d’Oliveira & Associates on Steps to Take After a Car Crash 2Health News:Da Vinci Surgical Robot Lawyers at Wright & Schulte LLC Note Recent Developments in Da Vinci Robot Lawsuit Trial 2Health News:Da Vinci Surgical Robot Lawyers at Wright & Schulte LLC Note Recent Developments in Da Vinci Robot Lawsuit Trial 3Health News:Da Vinci Surgical Robot Lawyers at Wright & Schulte LLC Note Recent Developments in Da Vinci Robot Lawsuit Trial 4Health News:Janet Hall Svisdahl Announces Release of ‘Cooking with Spirits for the Spirit’ 2Health News:ASGE and ASGE foundation hold Crystal Awards dinner as part of Digestive Disease Week®, May 19, in Orlando 2Health News:ASGE and ASGE foundation hold Crystal Awards dinner as part of Digestive Disease Week®, May 19, in Orlando 3Health News:ASGE and ASGE foundation hold Crystal Awards dinner as part of Digestive Disease Week®, May 19, in Orlando 4Health News:ASGE and ASGE foundation hold Crystal Awards dinner as part of Digestive Disease Week®, May 19, in Orlando 5Health News:ASGE and ASGE foundation hold Crystal Awards dinner as part of Digestive Disease Week®, May 19, in Orlando 6Health News:ASGE and ASGE foundation hold Crystal Awards dinner as part of Digestive Disease Week®, May 19, in Orlando 7Health News:AGA Research Foundation Research Scholar Awards advance the work of promising gastroenterologists 2
... a specialty,bank consulting firm, has moved its affiliation to ... independent office of,John Hancock Financial Network in Buffalo, NY, ... to the entire network nationally,announced Peter Gordon, President of ... are excited to be able to offer this specialized ...
... In a statewide survey of medical professionals, 38 physician-scientists ... Medical Center (LA BioMed) are honored for being ... issue of Los Angeles magazine. , Key Professional Media, ... professionals to compile the 2008 list of Southern California ...
... of West,Virginia, Inc. and the Nitro Walmart Marketplace are working ... significant,increase for unexpected emergency needs assistance. , ... events, being held this Friday and,Saturday, more than $20,000 in ... food that will help thousands of area families pay bills, ...
... Clinically Proven, Anti-Aging REVALESKIN(R) Skin Care Brand Launches ... and REVALESKIN(R) Chest/Decolletage Rejuvenating Treatment, All Exclusively Formulated ... , CORAL GABLES, ... of the extraordinarily successful introduction of the core ...
... , , NEW YORK, Dec. 4 ... that it has repurchased 640,930 shares of WebMD Class A Common ... LLC, which was acquired by WebMD in December 2006. In ... in cash pursuant to the terms of the previously completed Subimo ...
... Dec. 4 The Perrigo Company,(Nasdaq: PRGO ... Desloratadine tablets (5 mg) has been settled with Perrigo ... been sued for patent infringement of,US Patent Nos. 6100274, ... ANDA,containing a Paragraph IV certification. Under the terms ...
Cached Medicine News:Health News:John Hancock Financial Network Offers Bank Owned Life Insurance Resource to Its Independent Career Firms Nationally 2Health News:John Hancock Financial Network Offers Bank Owned Life Insurance Resource to Its Independent Career Firms Nationally 3Health News:LA BioMed researchers among Southern California Super Doctors 2Health News:UniCare, Walmart Organize Circle of Hope To Help Mountain Mission Meet Increased Demand for Assistance 2Health News:Stiefel Laboratories Announces the Expansion of Its REVALESKIN(R) Skin Care Line With Three New Products 2Health News:Stiefel Laboratories Announces the Expansion of Its REVALESKIN(R) Skin Care Line With Three New Products 3Health News:Stiefel Laboratories Announces the Expansion of Its REVALESKIN(R) Skin Care Line With Three New Products 4Health News:Stiefel Laboratories Announces the Expansion of Its REVALESKIN(R) Skin Care Line With Three New Products 5Health News:Stiefel Laboratories Announces the Expansion of Its REVALESKIN(R) Skin Care Line With Three New Products 6Health News:WebMD Announces Repurchase of 640,930 of its Shares 2Health News:Perrigo Settles Desloratadine Patent Litigation 2Health News:Perrigo Settles Desloratadine Patent Litigation 3
(Date:5/17/2013)...  Sanofi (EURONEXT: SAN and NYSE: SNY ) ... , examining the selective JAK2 inhibitor SAR302503 for ... groups. The primary endpoint assessed the proportion of patients ... reported in previous trials, the most common adverse events ... be presented at an upcoming medical congress. ...
(Date:5/17/2013)...  Boston Scientific Corporation (NYSE: BSX ) ... Program May 21-24 in Paris . ... rich and diversified set of data this year at ... global chief medical officer, Boston Scientific.  "The primary endpoint ... NG PROMUS trial, which evaluated our Promus PREMIER ™ ...
(Date:5/16/2013)... , May 16, 2013  PTC Therapeutics, Inc., ... on Form S-1 with the U.S. Securities and Exchange ... of its common stock. The number of shares to ... have not been determined. (Logo:  http://photos.prnewswire.com/prnh/20010919/PTCLOGO ... are acting as joint book-running managers for the offering. ...
Breaking Medicine Technology:Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 3Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 4Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 5Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 6Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 2Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 3Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 4Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 5Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 6Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 7Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 8PTC Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering 2
... Patients with active moderate to severe rheumatoid arthritis ... or adalimumab (Humira ® ) and who were actively ... from baseline at week 10, and sustained response through ... 26 results from the RESTART study were presented for ...
... LLC, the image analysis and pattern recognition technology provider, ... of $244,479.25 under the U.S. Government,s Affordable Care Act. ... projects that show significant potential to produce new therapies, ... health care costs or advance the goal of curing ...
Cached Medicine Technology:New Anti-TNF Study Shows Patients With Rheumatoid Arthritis Receiving REMICADE® After Inadequate Response to Enbrel® or Humira® Demonstrate Marked Clinical Improvement 2New Anti-TNF Study Shows Patients With Rheumatoid Arthritis Receiving REMICADE® After Inadequate Response to Enbrel® or Humira® Demonstrate Marked Clinical Improvement 3New Anti-TNF Study Shows Patients With Rheumatoid Arthritis Receiving REMICADE® After Inadequate Response to Enbrel® or Humira® Demonstrate Marked Clinical Improvement 4New Anti-TNF Study Shows Patients With Rheumatoid Arthritis Receiving REMICADE® After Inadequate Response to Enbrel® or Humira® Demonstrate Marked Clinical Improvement 5New Anti-TNF Study Shows Patients With Rheumatoid Arthritis Receiving REMICADE® After Inadequate Response to Enbrel® or Humira® Demonstrate Marked Clinical Improvement 6New Anti-TNF Study Shows Patients With Rheumatoid Arthritis Receiving REMICADE® After Inadequate Response to Enbrel® or Humira® Demonstrate Marked Clinical Improvement 7Parascript Awarded $244,479.25 Affordable Care Act Grant From the U.S. Government 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: